IMPORTANCE Psychiatric reactions to life stressors are common in the general population and may result in immune dysfunction. Whether such reactions contribute to the risk of autoimmune disease remains unclear.
M ost humans are at some point during their lives exposed to trauma or significant life stressors, including loss of loved ones and exposure to various disasters or violence. 1, 2 While many individuals exposed to such adversities gradually recover, 1,3 a significant proportion goes on to develop severe psychiatric reactions, including posttraumatic stress disorder (PTSD) or acute stress reaction (also known as acute stress disorder) after life-threatening events, 4 or adjustment disorder triggered by an identifiable and stressful life change. 5 Individuals with such stress-related disorders experience an array of physiologic alterations, including disruption of the hypothalamic-pituitary-adrenal axis 6 and autonomic nervous system, 6,7 which in turn may influence multiple bodily systems, eg, immune function, 6, 8 and thereby susceptibility to disease. Manifested as abnormal immune reaction in specific organs or bodily systems, autoimmune disease may be influenced by psychiatric reactions to life stressors. Although animal data lend support to a potential link, 6 epidemiological evidence underpinning the association between stressrelated disorders and autoimmune diseases in humans is limited. Existing data are largely based on male, military samples 9-11 focusing on PTSD instead of all clinically confirmed, stress-related disorders. Further limitations entail cross-sectional designs, 10 small sample sizes, 9-11 and incomplete control of familial factors. 9, 10 The purpose of this study was to assess the association between stress-related disorders and subsequent risk of autoimmune disease, while controlling for familial factors through a sibling-based comparison, using nationwide registers in Sweden that include information on all medical diagnoses and family links.
Methods

Study Design
Based on the Swedish Population and Housing Census in 1980, we identified all Swedish-born individuals living in Sweden in 1980. These individuals were followed up from January 1, 1981 , by cross-linking the census data to the National Patient Register, Multi-Generation Register, Prescribed Drug Register, Cause of Death Register, and Migration Register using the national identification numbers unique for all Swedish inhabitants. The study was approved by the Regional Ethics Review Board in Stockholm; the requirement of informed consent is waived in register-based studies in Sweden.
We compiled an exposed cohort of all individuals who received their first diagnosis of a stress-related disorder between January 1, 1981, and December 31, 2013 (Figure 1) . We excluded patients with a history of autoimmune disease or with conflicting information. Further, we excluded individuals born prior to 1932 to allow complete identification of family members from the Multi-Generation Register.
Stress-Related Disorders, Comorbidities, and Pharmaceutical Treatment
The Swedish National Patient Register includes nationwide information on inpatient diagnoses since 1987 (>80% of the country during [1981] [1982] [1983] [1984] [1985] [1986] , 12 and more than 80% of hospital-based outpatient specialist diagnoses (from both private and public caregivers) since 2001. Primary care is not yet covered by this register. We defined stress-related disorders as any first inpatient or outpatient visit with a primary diagnosis registered in the National Patient Register according to the eighth to 10th revisions of the International Classification of Diseases (ICD) codes 307 and 308.4 (ICD-8); 308 and 309 (ICD-9); and F43 (ICD-10) (eTable 1 in the Supplement). Stress-related disorders were further divided into PTSD (ICD-9: 309B; ICD-10: F43.1), acute stress reaction (ICD-9: 308, 309A; ICD-10: F43.0), and adjustment disorder and other stress reactions (ICD-8: 307 and 308.4; ICD-9: 309X; ICD-10: F43.2, F43.8, and F43.9). Because PTSD might initially be diagnosed as other stressrelated disorders (most likely as acute stress reaction 13 ), we classified all patients receiving a diagnosis of PTSD within 1 year after their first stress-related disorder diagnosis as patients with PTSD. Further, for patients diagnosed as having a stressrelated disorder in 2001 onward, we classified the severity of stress-related disorders by the type (ie, inpatient, outpatient, or both) and intensity (ie, duration of inpatient stay and/or frequency of outpatient visits) of psychiatric care during the first year after diagnosis.
Other psychiatric disorders are common comorbidities of stress-related disorders.
14, 15 We therefore considered other psychiatric diagnoses recorded more than 3 months before the first stress-related disorder diagnosis as "history of other psychiatric disorders," whereas diagnoses from 3 months before to 1 year after the first diagnosis of stress-related disorder were recorded as "psychiatric comorbidities." Diagnoses of other psychiatric disorders were similarly obtained from the National Patient Register (ICD-8: 290-319 except 307 and 308.4; ICD-9: 290-319 except 308 and 309; and ICD-10: F10-F99 except for F43). Selective serotonin reuptake inhibitors (SSRIs) are the recommended first-line pharmacotherapy for PTSD with documented effectiveness for its core symptoms. 16 To study the potential role of this treatment on the association of interest, we retrieved information on the dispensing of SSRIs (Anatomical Therapeutic Chemical code N06AB) from the Prescribed Drug Register, available from July 2005. We defined SSRI users as individuals who filled 2 or more prescriptions of SSRIs within the first year after diagnosis. The duration of treatment was the number of days between the first and the last dispensation. The average dosage was then calculated by dividing cumulative defined daily dose 17 by the duration of treatment.
Population-Matched Unexposed Cohort
We randomly selected 10 persons per exposed patient, individually matched by birth year and sex, from the study base who were free of stress-related disorders and autoimmune diseases at the diagnosis date of the index patient.
Sibling Cohort
Because multiple factors that cluster within families may be associated with both stress-related disorders and autoimmune diseases, we further conducted a sibling-based comparison including both patients with stress-related disorders and their full siblings, ie, with the same biological mother and father.
Follow-up
We followed up all participants from the index date until the first diagnosis of autoimmune disease, death, emigration, or the end of study (December 31, 2013) , whichever occurred first.
The follow-up of unexposed individuals or siblings was additionally censored if they were later diagnosed as having stressrelated disorders. These individuals were then moved to the exposed group. To reduce risks of reverse causality and surveillance bias (ie, increased probability of detecting autoimmune diseases in patients with stress-related disorder due to increased medical surveillance), we excluded the first year of follow-up in all analyses (see flexible parametric survival models in eFigure 1 in the Supplement).
Autoimmune Diseases
Information on autoimmune diseases was retrieved from the National Patient Register. In total, we considered 41 autoimmune diseases, 18 using their corresponding ICD codes (eTable 1intheSupplement (1964-present) and the Swedish National Outpatient Register (2001-present) .
Those in the population-matched cohort were individually matched 1:10 (by sex and birth year).
a The first year of follow-up was excluded for calculating the accumulated person-years.
b Eligible unexposed individuals were the ones without stress-related disorders and autoimmune diseases at the diagnosis of the index patient. The matching was performed using the density sampling method.
c Among the unexposed individuals, 15243 (1.4%) received a diagnosis of stress-related disorder during follow-up and contributed to the exposed group after the diagnosis.
d A subgroup of the exposed cohort involved in the population-matched cohort, including only exposed patients with trackable full siblings without stress-related disorders and autoimmune diseases at the diagnosis date of the index patient.
e Among the full siblings, 5295 (4.2%) received a diagnosis of stress-related disorders during follow-up and contributed to the exposed group after the diagnosis.
National Patient Register. Family history of autoimmune disease was defined as having any first-degree relatives (biological parents, siblings, or children) with any included autoimmune disease recorded in the National Patient Register. We used the most updated information before the index date for all analyses. Additionally, based on the National Patient Register, we calculated the number of health care visits (including both inpatient stay and outpatient visit, for any reason) for all participants during the first year after study entry, as a proxy of medical surveillance level during follow-up. Because exposed patients received intensive medical care during the first month after their diagnoses, we removed the first month after study entry from this calculation.
Statistical Analysis
We used conditional Cox models to estimate hazard ratios (HRs) with 95% CIs of autoimmune diseases in relation to previous stress-related disorders using time after the index date as the underlying time scale.
In the population-matched cohort, we stratified all analyses by matching identifiers (birth year and sex) and adjusted for education level (<9 years, 9-12 years, >12 years, or unknown), family income (top 20%, middle, lowest 20%, or unknown), marital status (single, married/cohabiting, or divorced/widowed), Charlson Comorbidity Index score (0, 1, or ≥2), family history of autoimmune disease (yes or no), and history of other psychiatric disorders (yes or no). We analyzed all stress-related disorders as 1 group followed by separate analyses for PTSD, acute stress reaction, and adjustment disorder and other stress reactions. Also, we separately calculated the HRs for sex, age at index date (by quartiles, ≤33, 34-41, 42-50, or ≥51 years) , calendar year at index date (1981-1990, 1991-2000, or 2001-2013) , time since index date (1-4 years, 5-9 years, or ≥10 years), family history of autoimmune disease (yes or no), history of other psychiatric disorders (yes or no), and the frequency of health care visits during the first year (0-1 or ≥2 times). We assessed the differences of HRs by introducing an interaction term to the Cox models. Besides the aforementioned relative measures of association, we calculated absolute rate difference with 95% CIs.
We further performed subgroup analyses by psychiatric comorbidity, as well as the type and intensity of psychiatric care received within 1 year after the diagnosis (among patients diagnosed in 2000 onward). For patients diagnosed since July 2005, we examined the potential effect of SSRI use on the association between stress-related disorders and autoimmune disease. The Wald test was used to examine the difference in subgroups (for nominal variables) or to test the potential dosedependent effect (for ordinal variables).
In addition to a diagnosis of any autoimmune disease, we examined the risk of multiple autoimmune syndromes (ie, having ≥3 autoimmune diseases), 20 individual autoimmune diseases (with ≥100 identified cases in the population-matched cohort), as well as 9 major groups of autoimmune diseases (diseases of endocrine, nervous, digestive, skin system, inflammatory arthritis, connective tissue disorders, vasculitis, hematological diseases, and others). Similar analyses were conducted in the sibling cohort. We used conditional Cox models stratified by family identifier and adjusted for similar variables as in the population-based comparison. HRs between population and sibling analyses were compared using a z test.
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To assess the robustness of the results to the definition of history of other psychiatric disorders, we re-ran the analyses by using a 6-month, instead of 3-month, period prior to stressrelated disorder to demark the "history of other psychiatric disorders." To further address the concern about surveillance bias, we plotted the cumulative incidence curves of autoimmune diseases among participants with more than 5 years of followup. Also, we used more stringent definitions of the outcome, including (1) at least 2 health care visits (inpatient stay or outpatient visit) with the same autoimmune disease as a diagnosis and (2) at least 1 inpatient stay with autoimmune disease as the main discharge diagnosis. Furthermore, the frequency of heath care visits during the first year was additionally adjusted as a continuous variable in the Cox models. To further reduce the possibility of reverse causality, we repeated the analyses by excluding the first 2 and 5 years after study entry. All analyses were conducted in SAS statistical software, version 9.4 (SAS Institute). A 2-sided P < .05 was considered statistically significant.
Results
Among 7 689 628 Swedish-born individuals, 125 896 patients with their first stress-related disorder diagnosed between 1981 and 2013 were identified. A total of 19 432 persons were excluded according to the exclusion criteria, leaving 106 464 eligible patients for further analyses (Figure 1 ). Then, 1 064 640 matched unexposed individuals and 126 652 full siblings (of 78 635 exposed patients), who were free of stress-related disorders and autoimmune diseases at the diagnosis date of the index patient, were included as reference groups.
The median age at diagnosis of stress-related disorders was 41 years and 40% of these patients were male ( Table 1) . Compared with unexposed individuals, exposed patients had a higher Charlson Comorbidity Index score, but lower education level and family income; they were also more likely to be divorced/ widowed and have a history of other psychiatric disorders.
During a mean follow-up of 10 years, we identified 8284 individuals with a newly diagnosed autoimmune disease among exposed patients (incidence rate, 9. 1 [95% CI, per 1000 person-years in the population-matched cohort and 9.0 [95% CI, .2] per 1000 person-years in the sibling cohort), 57 711 among matched unexposed individuals (incidence rate, 6.0 [95% CI, 5.9-6.0] per 1000 person-years), and 8151 among the siblings (incidence rate, 6.5 [95% CI, per 1000 person-years). This corresponds to an absolute rate difference of 3.12 (95% CI, 2.99-3.25) and 2.49 (95% CI, 2.23-2.76) per 1000 person-years compared with the populationand sibling-based reference groups, respectively. After controlling for confounders, the risk for autoimmune disease was increased among patients with stress-related disorders (HR, 1.36 [95% CI, ; Table 2 ) compared with matched unexposed individuals. Specifically, the HR was 1.46 (95% CI, 1.32-1.61) for PTSD, 1.35 (95% CI, ) for acute stress reactions, and 1.37 (95% 1.32-1.41) for adjustment disorder and other The presence of psychiatric comorbidity was associated with further elevated risk of autoimmune disease, eg, for all stress-related disorders, the HR was 1.47 (95% CI, 1.40-1.54) and 1.33 (95% CI, 1.29-1.37) for patients with and without psychiatric comorbidity, respectively (P for difference < .001) ( Table 3 and eTable 5 in the Supplement). Additionally, for patients with PTSD who initiated SSRI treatment (42.6% of all patients with PTSD), the observed excess risk decreased with persistent use of SSRIs during the first year after PTSD diagnosis (HR, 3.64 [95% CI, 2.00-6.62], 2.65 [95% CI, 1.57-4.45], and 1.82 [95% CI, 1.09-3.02] for duration ≤179, 180-319, and ≥320 days, respectively, irrespective of dosage level; P for trend = .03). However, no such findings were noted for other stress-related disorders.
The association of PTSD, but not other stress-related disorders, was stronger for multiple autoimmune syndromes than single autoimmune disease (HR, 1.46 [95% CI, 1.32-1.61] and 2.29 [95% CI, 1.72-3.04] for any and ≥3 autoimmune diseases, respectively; P for difference < .001; eFigure 2 in the Supplement). Except for hematological disorders, which only showed a risk elevation in the sibling-based comparison, stressrelated disorders were associated with elevated risks of all major groups of autoimmune diseases in both the populationmatched and sibling cohorts ( Figure 2 a A subgroup of the exposed cohort involved in the population-matched cohort, including only exposed patients with eligible full siblings.
b The Charlson Comorbidity Index is an approach of measuring comorbidities burden, with a weight of 1/2/3/6 assigned for each comorbidity category based on the reported risk of mortality or resource use. The sum of all the weights is the comorbidity index for an individual (possible range, 0-33).
A score of zero shows no comorbidities; the higher the score, the more likely the predicted outcome will result in mortality or higher medical resource use.
c Psychiatric disorders diagnosed before 3 months prior to the index date (ie, the diagnosis date of exposed patients or the diagnosis date of the index patient for matched unexposed individuals and siblings).
d Both inpatient and outpatient visits were included. The first month after study entry was removed from this calculation.
e Psychiatric disorders (other than stress-related disorders) diagnosed from 3 months before to 1 year after the diagnosis of stress-related disorders.
f Only for patients diagnosed in 2001 and onward. Only medical visit with stress-related disorders as main diagnosis was taken into account. Restricting to participants with more than 5 years of followup, patients with stress-related disorders had a higher cumulative incidence of autoimmune diseases compared with their matched unexposed individuals across the follow-up period (eFigure3intheSupplement). Additional adjustment for medical surveillance level yielded somewhat lower point estimates (eTable 6 in the Supplement) while changing the definitions for history of other psychiatric disorders and autoimmune disease, and the extension of the lag-time period yielded similar results (eTables 7 and 8 in the Supplement).
Discussion
Based on the nationwide population-and sibling-based comparisons, individuals who developed stress-related disorders after traumatic or other stressful events were at elevated risk of developing autoimmune disease. These associations were independent of history of other psychiatric disorders and became stronger with the presence of co-occurring psychiatric comorbidities. In addition, among patients with PTSD specifically, persistent use of SSRIs throughout the first year after diagnosis was associated with attenuated risk of autoimmune disease.
To our knowledge, this is the first study to address all stressrelated disorders and their associations with 41 distinct autoimmune diseases in men and women using both populationand sibling-based comparisons. The observed risk elevations showed heterogeneity for individual autoimmune diseases (eg, HR, 1.09 for rheumatoid arthritis but 1.49 for autoimmune thyroid disease), perhaps due to the differences in pathogenicity or the degree of autoimmunity between diverse autoimmune diseases.
22 These findings gain support from previous studies of male Vietnam War veterans 10,11 linking self-reported symptoms of PTSD to higher prevalence of a few selected autoimmune diseases. These studies are exclusively based on male samples and their cross-sectional designs limit inferences on causality. Yet, a recent prospective cohort study of US veterans also provided supportive evidence for the association between PTSD and a few types of autoimmune diseases 9 while the trauma exposure of these men (ie, war/combat) differed significantly from the general population.
Findings from the present study demonstrated that not only patients with PTSD, but also individuals with other and more common stress-related disorders, experienced considerably increased relative risk of autoimmune disease. Although the present findings are of etiologic importance, the relatively modest differences in incidence rates of autoimmune disease between the exposed and unexposed individuals (9.1 and 6.0 per 1000 person-years, respectively) do not provide direct evidence for altered clinical management or monitoring of persons with stress-related disorders.
The findings of this study are consistent with some biological evidence linking psychological stress and stressful events to varying impairments of immune function, 6,8 both of which lend support to a biopsychosocial model in the etiology of autoimmune disease. 23 Under stress, the activated autonomic nervous system might induce the dysregulation findings that patients with PTSD were at an increased risk of developing autoimmune disease, especially multiple autoimmune syndromes, with stronger association in younger age groups. An alternative mechanism is a potential change in lifestyle 6 after trauma exposure, such as sleep disruption, alcohol or substance abuse, and increased smoking, which may indirectly alter the risk of autoimmune disease. 29,30 A weaker association was observed for adjustment disorder and other stress-related reactions in the between-sibling comparison, compared with the population-based comparison, motivating further studies exploring potential genetic and early environmental contributors to the association. Study strengths include the application of populationbased cohort design: a complete follow-up of more than 100 000 patients diagnosed as having stress-related disorders during a 30-year period and a full-sibling comparison to address potential familial confounding. Furthermore, the large sample size provided sufficient statistical power to perform detailed subgroup analyses, including testing for the role of SSRI treatment. In addition, the availability of rich sociodemographic and medical information enabled considerations of a wide range of important confounding factors
Limitations
This study has several limitations. First, surveillance bias is a concern in the study. Multiple sensitivity analyses, including using extended lag times and different strategies for outcome ascertainment, restricting the analyses to severe autoimmune diseases, and adjusting for estimated medical surveillance level, suggested some but limited influence of surveillance bias in the reported associations. Second, diagnoses from primary care are not included in the Swedish Nation Patient Register, which may result in lower detection of stressrelated disorders and autoimmune diseases, particularly of lesssevere conditions. Also, no corroboration exists for the diagnoses of stress-related disorders in the Swedish National Patient Register and diagnostic practices of stress-related disorders have varied over time. PTSD was introduced in ICD-9; thus, patients with PTSD were previously either not diagnosed or diagnosed as having other stress-related disorders. Third, it is challenging to distinguish co-occurring other psychiatric disorders from the pre-existing ones using register data. This concern was partially relieved in sensitivity analysis with altered definitions revealing similar results. Fourth, there was limited information about potential causal pathways linking stressrelated disorders to autoimmune diseases. The potential role of other unmeasured factors (eg, infections preceding autoimmune diseases, 31 alterations in health-related behavior, or the use of other medications) need to be addressed in future studies. Fifth, despite showing stronger associations among younger participants, the present study had limited statistical power to assess the association between stress-related disorder and autoimmune disease in early life.
Conclusions
In this Swedish cohort, exposure to a stress-related disorder was significantly associated with increased risk of subsequent autoimmune disease, compared with matched unexposed individuals and with full siblings. Further studies are needed to better understand the underlying mechanisms. a Cox models were stratified by matching identifiers (birth year and sex), and adjusted for education level, family income, marital status, Charlson comorbidity index score, family history of autoimmune disease, and history of other psychiatric disorders. The first year of follow-up was excluded for all analyses. b P value was derived from interaction test by incorporating an interaction term to the Cox model. c Psychiatric disorders diagnosed before 3 months prior to the index date (i.e., the diagnosis date of exposed patients or the diagnosis date of the index patient for matched unexposed individuals and siblings). d Both inpatient stay and outpatient visit were included. The first month after study entry was removed from this calculation. a Cox models were stratified by family identifier, and adjusted for sex, age at study entry, education level, family income, marital status, Charlson comorbidity index score, family history of autoimmune disease, and history of other psychiatric disorders. The first year of follow-up was excluded for all analyses. b P value was derived from interaction test by incorporating an interaction term to the Cox model. c Psychiatric disorders diagnosed before 3 months prior to the index date (i.e., the diagnosis date of exposed patients or the diagnosis date of the index patient for matched unexposed individuals and siblings). d Both inpatient stay and outpatient visit were included. The first month after study entry was removed from this calculation.
